We found companies at discovery stage and exit at IND-stage

BSM exploits market inefficiencies that are typical for discovery / preclinical stage biotechs

• • Low to moderate development costs but comparatively high likelihood to reach exit due to high stage-transition success probabilities
  • Observed valuations at investment (early discovery) lower than predicted by eNPV models
  • Observed value gains after investment (milestone to milestone) higher than predicted by eNPV models

Analysis of VC-returns suggests that early-stage biotech funds provide higher returns than late-stage biotech funds and outperform funds that invest in other asset classes

We build portfolio companies based on in-licensed or acquired assets and technologies, sourced worldwide

We de-risk by

• • Thorough evaluation of investment opportunities through partnership with Bioscience Valuation BSV GmbH
  • AI-driven molecular target selection & validation
  • Maximizing Sharp Ratios (expected return for each unit of risk) through our unique business model